Global Artificial Intelligence regulation in life sciences
Life sciences companies face a fast-changing regulatory and intellectual property environment as governments in the US, UK, EU, and China develop new rules for Artificial Intelligence. The focus is shifting toward patient safety, data governance, ethics, and cross-border compliance in drug development and commercialization.